SCHEMBL1724136

SCHEMBL1724136

Nc1ccc(-c2cnccn2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PI4KA P42356 1/20 0.47
PIK3CG P48736 1/20 0.47
PI4KB Q9UBF8 1/20 0.47
HSP90AA1 P07900 1/20 0.46
MAPT P10636 2/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
DYRK1A Q13627 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP19A1 P11511 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALOX5AP P20292 2/20 0.44
FEN1 P39748 2/20 0.44
PIM1 P11309 2/20 0.44
PIM2 Q9P1W9 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11541937 0.80 CYP2D6 (0.60) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL8467929 0.79 CYP2D6 (0.51) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL30726498 0.77 ALOX5AP (0.49) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL1722976 0.76 CYP2A6 (0.55) PIK3CDPIK3CAPI4KAPIK3CGPI4KB
SCHEMBL21241338 0.76 PORCN (0.50) MAPTCYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL1257460 0.75 PIK3CD (0.73) PIK3CDMAPTMKNK1MKNK2DYRK1A
SCHEMBL29740321 0.75 PIK3CD (0.73) PIK3CDMAPTMKNK1MKNK2DYRK1A
SCHEMBL19376887 0.74 HSP90AA1 (0.54) PIK3CDHSP90AA1MAPTMKNK1MKNK2
SCHEMBL31593062 0.74 HSP90AA1 (0.54) PIK3CDHSP90AA1MAPTMKNK1MKNK2
SCHEMBL31593067 0.74 HSP90AA1 (0.54) PIK3CDHSP90AA1MAPTMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2025-12-23 US disclosed
US-12202826-B2 N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway REDX PHARMA PLC (GB) 2025-01-21 US disclosed
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2024-01-11 US disclosed
US-20230365549-A1 N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY REDX PHARMA PLC (GB) 2023-11-16 US disclosed
US-20230365549-A1 N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY REDX PHARMA PLC (GB) 2023-11-16 US disclosed
US-20230365549-A1 N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY REDX PHARMA PLC (GB) 2023-11-16 US disclosed
CN-111662228-B Pyridone acyl biarylamine compounds and uses thereof 中国医学科学院药物研究所 2023-07-28 CN disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11643408-B2 N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway REDX PHARMA PLC (GB) 2023-05-09 US disclosed
US-8546396-B2 N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators IRM LLC (BM) 2013-10-01 US disclosed
EP-2623493-A1 N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators IRM LLC (BM) 2013-08-07 EP disclosed
EP-2403832-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2012-01-11 EP disclosed
US-20110237573-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2011-09-29 US disclosed
US-20110237573-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2011-09-29 US disclosed
US-20110237573-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2011-09-29 US disclosed
WO-2010101849-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2010-09-10 WO disclosed
WO-2010101849-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS IRM LLC (BM) 2010-09-10 WO disclosed
US-7696217-B2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. (US) 2010-04-13 US disclosed
US-7696217-B2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. (US) 2010-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 PIK3CD 2075/4885PIK3CA 2545/4885PIK3CB 1251/4885
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 PIK3CD 2075/4885PIK3CA 2545/4885PIK3CB 1251/4885
US-12202826-B2 N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway WNT1, WNT3, CTNNB1 PIK3CD 267/4885PIK3CA 270/4885PIK3CB 234/4885
US-20230365549-A1 N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY WNT1, WNT3, CTNNB1 PIK3CD 267/4885PIK3CA 270/4885PIK3CB 234/4885
US-20110237573-A1 N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS WNT1, CTNNB1, WNT3A PIK3CD 1686/4885PIK3CA 1512/4885PIK3CB 1379/4885
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 PIK3CD 2075/4885PIK3CA 2545/4885PIK3CB 1251/4885
US-11643408-B2 N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway WNT1, WNT3, CTNNB1 PIK3CD 267/4885PIK3CA 270/4885PIK3CB 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.